Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

3C-FE

Add links
From Wikipedia, the free encyclopedia

3C-FE
Clinical data
Other names4-(2-Fluoroethoxy)-3,5-dimethoxyamphetamine; 3C-FEM; 3C-Fluoroescaline
Routes of
administration		Unknown[1][2][3]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1][2][3]
Identifiers
  • 1-[4-(2-fluoroethoxy)-3,5-dimethoxyphenyl]propan-2-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H20FNO3
Molar mass257.305 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C(C(=C1)OC)OCCF)OC)N
  • InChI=1S/C13H20FNO3/c1-9(15)6-10-7-11(16-2)13(18-5-4-14)12(8-10)17-3/h7-9H,4-6,15H2,1-3H3
  • Key:BILSAOCOBOYWEO-UHFFFAOYSA-N

3C-FE, also known as 4-(2-fluoroethoxy)-3,5-dimethoxyamphetamine or as 3C-fluoroescaline, is a serotonin receptor modulator of the phenethylamine, amphetamine, and 3C families.[1][4][5][3][2] It is the amphetamine (α-methyl) derivative of the psychedelic drug fluoroescaline (FE).[1][3][2]

According to Daniel Trachsel in his book Phenethylamine: von der Struktur zur Funktion and other publications, 3C-FE is inactive at doses of up to 24 mg orally, but has not been sufficiently investigated.[1][2] Hence, its properties and effects in humans remain unknown.[1][2][3]

The drug shows weak affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 5,987–12,000 nM and 8,400–>10,000 nM, respectively).[3][1][2] It is an agonist of the serotonin 5-HT2A and 5-HT2B receptors (EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) = 120 nM (102%) and 800 nM (29%), respectively).[2]

The chemical synthesis of 3C-FE has been described.[5]

3C-FE was first described in the scientific literature by Daniel Trachsel in 2002.[5][1][3]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. 1 2 3 4 5 6 7 8 Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021). "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology. 12 794254. doi:10.3389/fphar.2021.794254. PMC 8865417. PMID 35222010.
  3. 1 2 3 4 5 6 7 Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
  4. ↑ Shulgin A, Manning T, Daley PF (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
  5. 1 2 3 Trachsel D (2002). "Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur-Aktivitätsbeziehungen, Mitteilung 1, Mescalin Derivate" [Synthesis of new (phenylalkyl)amines for the investigation of structure-activity relationships, Communication 1, Mescaline derivatives]. Helvetica Chimica Acta. 85 (9): 3019–3026. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=3C-FE&oldid=1347694579"